Cbl Protein (Casitas B Lineage Lymphoma) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
:: infobox .infobox-protein
| CBL Protein (Casitas B-lineage Lymphoma) | |
|---|---|
| Gene | CBL |
| UniProt | P22681 |
| Molecular Weight | ~100 kDa |
| Subcellular Localization | Cytoplasm |
| Protein Family | RING-type E3 ubiquitin ligase family |
| Aliases | CBL, CBL-B, RNF55 |
===
CBL (Casitas B-lineage lymphoma) is an E3 ubiquitin ligase that functions as a negative regulator of receptor tyrosine kinase signaling. CBL proteins play crucial roles in controlling cell proliferation, differentiation, and survival. In the nervous system, CBL is involved in synaptic plasticity, neuronal development, and has been implicated in neurodegenerative diseases and cancer.
CBL is a RING-type E3 ubiquitin ligase containing an N-terminal tyrosine kinase binding (TKB) domain, a linker region, and a C-terminal RING finger domain. The protein is approximately 906 amino acids and functions as an adaptor protein and ubiquitin ligase.
CBL regulates multiple signaling pathways:
CBL mutations are associated with:
CBL functions as a tumor suppressor, and mutations are found in:
CBL syndrome (CBL-ML) involves developmental delay, dysmorphic features, and predisposition to leukemia.
CBL-based therapies target:
The study of Cbl Protein (Casitas B Lineage Lymphoma) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.